Table 1.
Baseline characteristics
| SOF/DCV (n = 27) | Control (n = 28) | P value | |
|---|---|---|---|
| Age (years), median (IQR) | 43 (37–52) | 47.5 (37–53) | 0.643 |
| Male, n (%) | 12 (44) | 14 (50) | 0.789 |
| BMI (kg), median (IQR) | 27 (25–33) | 26 (23–30) | 0.293 |
| Comorbidities, n (%) | 13 (48) | 8 (27) | 0.171 |
| Oxygen saturation | 98 (97–98) | 98 (97–99) | 0.834 |
| SBP (mmHg), median (IQR) | 120 (110–130) | 120 (110–128) | 0.572 |
| DBP (mmHg), median (IQR) | 80 (75–80) | 80 (80–80) | 0.821 |
| Ground glass opacity, n (%) | |||
| 5% | 3 (11) | 6 (21) | 0.646 |
| 25% | 7 (26) | 6 (21) | |
| 50% | 16 (59) | 16 (57) | |
| 75% | 1 (4) | 0 (0) | |
SOF/DCV, sofosbuvir/daclatasvir; SBP, systolic blood pressure; DBP, diastolic blood pressure.
P values calculated using Fisher’s exact test for categorical outcomes and Mann–Whitney U-test for continuous outcomes.